Beverly J Lange

Summary

Affiliation: The Children's Hospital of Philadelphia
Country: USA

Publications

  1. ncbi request reprint The old grey mare, she ain't what she used to be. Is she?: (commentary on Kaspers et al., page 539)
    Beverly Lange
    Pediatric Oncology, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19003, USA
    Pediatr Blood Cancer 47:535-6. 2006
  2. ncbi request reprint Mortality in overweight and underweight children with acute myeloid leukemia
    Beverly J Lange
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    JAMA 293:203-11. 2005
  3. pmc Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group
    Beverly J Lange
    University of Pennsylvania School of Medicine and The Children s Hospital of Philadelphia, Division of Oncology, Philadelphia, PA, USA
    Blood 111:1044-53. 2008
  4. pmc Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia
    Beverly J Lange
    The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Pediatr Blood Cancer 57:398-405. 2011
  5. ncbi request reprint Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group
    Beverly J Lange
    Division of Oncology, Children s Hospital of Philadelphia, PA, USA
    Blood 99:825-33. 2002
  6. doi request reprint Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group
    Richard Aplenc
    Children s Hospital of Philadelphia, Center for Clinical Epidemiology Biostatistic, 3615 Civic Center Blvd, 916G ARC, Philadelphia, PA 19104 4318, USA
    J Clin Oncol 26:2390-3295. 2008
  7. ncbi request reprint Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941
    Beverly J Lange
    Children s Hospital of Philadelphia, Philadelphia, PA, USA
    J Clin Oncol 22:150-6. 2004
  8. pmc Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group
    Richard Aplenc
    Pediatric Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Blood 108:74-80. 2006
  9. doi request reprint Bone-marrow relapse in paediatric acute lymphoblastic leukaemia
    L Charles Bailey
    Division of Oncology, Children s Hospital of Philadelphia, and University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Lancet Oncol 9:873-83. 2008
  10. ncbi request reprint Factitious fungus in two children with cancer receiving liposomal amphotericin
    Michael J Fisher
    Department of Pediatrics, Children s Hospital of Philadelphia, Pennsylvania 19104, USA
    J Pediatr Hematol Oncol 24:360-3. 2002

Detail Information

Publications38

  1. ncbi request reprint The old grey mare, she ain't what she used to be. Is she?: (commentary on Kaspers et al., page 539)
    Beverly Lange
    Pediatric Oncology, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19003, USA
    Pediatr Blood Cancer 47:535-6. 2006
  2. ncbi request reprint Mortality in overweight and underweight children with acute myeloid leukemia
    Beverly J Lange
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    JAMA 293:203-11. 2005
    ..Overweight children with AML seem to experience excess life-threatening and fatal toxicity. Nothing is known about how weight affects outcomes in pediatric AML...
  3. pmc Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group
    Beverly J Lange
    University of Pennsylvania School of Medicine and The Children s Hospital of Philadelphia, Division of Oncology, Philadelphia, PA, USA
    Blood 111:1044-53. 2008
    ..No new agent improved outcomes; experience may have contributed to better results time...
  4. pmc Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia
    Beverly J Lange
    The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Pediatr Blood Cancer 57:398-405. 2011
    ..To assess associations of soluble IL-2 receptor alpha (sIL-2rα) concentration with outcomes in pediatric acute myeloid leukemia (AML) in a phase 3 trial of IL-2 therapy...
  5. ncbi request reprint Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group
    Beverly J Lange
    Division of Oncology, Children s Hospital of Philadelphia, PA, USA
    Blood 99:825-33. 2002
    ..These data demonstrate that DDI improves EFS of patients younger than 10 years of age with intermediate-risk ALL...
  6. doi request reprint Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group
    Richard Aplenc
    Children s Hospital of Philadelphia, Center for Clinical Epidemiology Biostatistic, 3615 Civic Center Blvd, 916G ARC, Philadelphia, PA 19104 4318, USA
    J Clin Oncol 26:2390-3295. 2008
    ....
  7. ncbi request reprint Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941
    Beverly J Lange
    Children s Hospital of Philadelphia, Philadelphia, PA, USA
    J Clin Oncol 22:150-6. 2004
    ..In Children's Cancer Group Pilot Study CCG-2941, we assessed toxicity and feasibility of substituting 4 mg of DNR with 1 mg of IDA in intensive-timing daunorubicin-based induction therapy (DNR/DNR) used in CCG-2891...
  8. pmc Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group
    Richard Aplenc
    Pediatric Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Blood 108:74-80. 2006
    ..Fewer black children than expected had an available family marrow donor...
  9. doi request reprint Bone-marrow relapse in paediatric acute lymphoblastic leukaemia
    L Charles Bailey
    Division of Oncology, Children s Hospital of Philadelphia, and University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Lancet Oncol 9:873-83. 2008
    ..Although better drugs are needed, introduction of new agents into clinical trials in paediatric disease has been difficult. Innovative trial designs and use of valid surrogate endpoints may expedite this process...
  10. ncbi request reprint Factitious fungus in two children with cancer receiving liposomal amphotericin
    Michael J Fisher
    Department of Pediatrics, Children s Hospital of Philadelphia, Pennsylvania 19104, USA
    J Pediatr Hematol Oncol 24:360-3. 2002
    ..These cases underscore the importance of establishing a microbiologic diagnosis in cases of presumed fungal infection...
  11. doi request reprint Proactive enteral tube feeding in pediatric patients undergoing chemotherapy
    Nancy Sacks
    Department of Clinical Nutrition, Division of Oncology, Center for Childhood Cancer Research, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 61:281-5. 2014
    ..To determine feasibility and safety of proactive enteral tube feeding (ETF) in pediatric oncology patients...
  12. ncbi request reprint Evolving concepts of management of febrile neutropenia in children with cancer
    Elmar Orudjev
    Division of Oncology, The Children s Hospital of Philadelphia, The University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Med Pediatr Oncol 39:77-85. 2002
    ..Recent investigations of febrile neutropenia in pediatric cancer patients have identified subsets of low-risk patients who can be managed with less antibiotic therapy than previously recommended standards...
  13. ncbi request reprint Central nervous system juvenile xanthogranuloma with malignant transformation
    Andrea Orsey
    Division of Pediatric Oncology, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Pediatr Blood Cancer 50:927-30. 2008
    ..Despite further chemotherapy, the patient died of disease progression. This case highlights the clinical and pathological heterogeneity of JXG and the difficulty of treating multi-focal CNS disease...
  14. ncbi request reprint Infections with viridans group streptococci in children with cancer
    Anne F Reilly
    Division of Oncology, Department of Pediatrics, The Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Pediatr Blood Cancer 49:774-80. 2007
    ..Routine systemic antimicrobial prophylaxis against VGS infection has not been proven effective. Current recommendations include appropriate antibiotic therapy and intensive supportive care...
  15. ncbi request reprint Identifying psychosocial risk indicative of subsequent resource use in families of newly diagnosed pediatric oncology patients
    Anne E Kazak
    Division of Oncology, The Children s Hospital of Philadelphia, Room 1486 CHOP North, 34th St and Civic Center Blvd, Philadelphia, PA 19104, USA
    J Clin Oncol 21:3220-5. 2003
    ..Additional study aims were to examine concordance among family and staff reports of psychosocial risk, changes in risk status over time, and to predict the use of psychosocial resources during the first months of treatment...
  16. ncbi request reprint Isolated extramedullary relapse in acute myeloid leukemia: A retrospective analysis
    Jill P Ginsberg
    Division of Oncology, The Children s Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Med Pediatr Oncol 38:387-90. 2002
    ..Little is known about the characteristics and outcome of children with acute myeloid leukemia (AML) experiencing an isolated extramedullary relapse (IEMR)...
  17. ncbi request reprint Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy
    Michael J Fisher
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Pediatr Blood Cancer 43:780-4. 2004
    ..Larger studies will help clarify these findings...
  18. ncbi request reprint Long-term (15 years) outcome in an infant with metastatic adrenocortical carcinoma
    Diva D De Leon
    Division of Endocrinology, Department of Pediatrics, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    J Clin Endocrinol Metab 87:4452-6. 2002
    ..His motor and speech development was delayed. After mitotane was discontinued he demonstrated catch-up growth. This case shows successful long-term outcome and recovery from the toxic effects of mitotane...
  19. ncbi request reprint Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia
    Richard Aplenc
    Children s Hospital of Philadelphia, PA 19104, USA
    Cancer Res 65:2482-7. 2005
    ..These data provide evidence that the MTHFR C677T polymorphism is a common genetic variant conferring a moderate relative risk and a high attributable risk for relapse in pediatric ALL patients...
  20. ncbi request reprint Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia
    Richard Aplenc
    Department of Pediatrics, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Br J Haematol 125:421-34. 2004
    ..This review summarizes current research on the impact of genetic variation in drug-processing genes in paediatric ALL and reviews important methodological and statistical issues presently challenging the field of pharmacogenetics...
  21. ncbi request reprint CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia
    Richard Aplenc
    Children s Hospital of Philadelphia, Philadelphia, University of Pennsylvania, PA, Children s Cancer Study Group, Arcadia, CA, USA
    Br J Haematol 122:240-4. 2003
    ..CYP3 genotypes may not significantly modify the risk of relapse in childhood ALL, but may modify the risk of toxicity...
  22. ncbi request reprint Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group
    Todd A Alonzo
    Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    J Pediatr Hematol Oncol 24:627-35. 2002
    ....
  23. ncbi request reprint Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia
    Eric L Sievers
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA the Department of Pediatrics, University of Washington, Seattle, WA 98109, USA
    Blood 101:3398-406. 2003
    ..Among patients in whom a marrow sample was available for analysis at the end of consolidation therapy, overall survival at 3 years was 41% versus 69% for patients with and without occult leukemia, respectively (P =.0058)...
  24. ncbi request reprint Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia
    Lillian Sung
    Division of Haematology Oncology, Hospital for Sick Children, Toronto, ON, Canada
    Blood 110:3532-9. 2007
    ..Thus, age, ethnicity, and BMI were important contributors to IRM. Fungi and Gram-positive cocci were the most common organisms associated with IRM and, in particular, Aspergillus species was the largest contributor to infectious deaths...
  25. ncbi request reprint Obesity and outcome in pediatric acute lymphoblastic leukemia
    Anna M Butturini
    Childrens Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA
    J Clin Oncol 25:2063-9. 2007
    ..To evaluate the effect of obesity (defined as a body mass index > 95th percentile for age and sex at diagnosis) on outcome of pediatric acute lymphoblastic leukemia (ALL)...
  26. ncbi request reprint Outcomes in childhood AML in the absence of transplantation in first remission--Children's Cancer Group (CCG) studies 2891 and CCG 213
    Sharon M Castellino
    ETSU Quillen College of Medicine, Johnson City, Tennessee, USA
    Pediatr Blood Cancer 50:9-16. 2008
    ..The majority of childhood acute myeloid leukemia (AML) patients lack a matched-related bone marrow transplant (BMT) donor in first remission...
  27. pmc Clinical implications of FLT3 mutations in pediatric AML
    Soheil Meshinchi
    Fred Hutchinson Cancer Research Center, Clinical Research Division, D5 380, 1100 Fairview Ave N, Seattle, WA 98103, USA
    Blood 108:3654-61. 2006
    ..001) or with FLT3/WT (55%, P < .001). ITD-AR defines the prognostic significance in FLT3/ITD-positive AML, and ITD-AR greater than 0.4 is a significant and independent prognostic factor for relapse in pediatric AML...
  28. ncbi request reprint Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival
    Steven Neudorf
    American Family Life Assurance Company AFLAC Cancer Center, Emory University Children s Healthcare, Atlanta, GA, USA
    Blood 103:3655-61. 2004
    ..014) were associated with improved relapse-free survival (RFS). Our results show that children older than 10 years are at higher risk for developing severe GVHD; acute GVHD is associated with favorable RFS...
  29. ncbi request reprint Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia
    Donna L Johnston
    Division of Hematology Oncology, Children s Hospital of Eastern Ontario, Ottawa, Ontario, Canada
    J Clin Oncol 23:9172-8. 2005
    ..CNS relapse of pediatric acute myeloid leukemia (AML) is an infrequent occurrence. This review examines the risk factors and therapy used for patients with an isolated CNS relapse...
  30. ncbi request reprint Obesity in pediatric oncology
    Paul C Rogers
    Children s and Women s Hospital and University of British Columbia, Vancouver, British Columbia, Canada
    Pediatr Blood Cancer 45:881-91. 2005
    ....
  31. pmc Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961
    Draga Barbaric
    Division of Hematology Oncology BMT, BC s Children s Hospital, Vancouver, BC, Canada
    Blood 109:2314-21. 2007
    ..There was no significant outcome difference between DS-associated AML-M0 and non-M0 children. This study suggests that intensively treated non-DS-associated AML-M0 children have an inferior outcome compared with children with non-M0 AML...
  32. ncbi request reprint A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962)
    Helen A Kurre
    Clinical Services Administration, Children s Hospital and Regional Medical Center, Seattle, Washington, USA
    J Pediatr Hematol Oncol 24:175-81. 2002
    ..a newer chemotherapeutic agent used for treating acute lymphoblastic leukemia, with native Escherichia coli L-asparaginase in induction, delayed intensification 1 and delayed intensification 2...
  33. ncbi request reprint Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children
    Martyn T Smith
    Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley 94720 7360, USA
    Blood 100:4590-3. 2002
    ..The inactivating NQO1 polymorphism is associated with an increased risk of de novo leukemia with MLL translocations in infants and children...
  34. pmc Structural and numerical variation of FLT3/ITD in pediatric AML
    Soheil Meshinchi
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington Medical Center, Seattle, USA
    Blood 111:4930-3. 2008
    ..035), while the presence of more than 1 ITD was not clinically significant. Physical characteristics including the length of FLT3/ITD may influence FLT3 activation state by altering its structure and may impact response to therapy...
  35. ncbi request reprint XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report
    Parinda A Mehta
    Cincinnati Children s Hospital and Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, USA
    Blood 107:39-45. 2006
    ..These data, representing the only data in pediatric AML, suggest that XPD genotype does not affect the etiology or outcome of childhood AML...
  36. ncbi request reprint Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children's Cancer Group
    Kathryn E Dusenbery
    University of Minnesota, Minneapolis, USA
    J Pediatr Hematol Oncol 25:760-8. 2003
    ..To describe features of patients with acute myeloid leukemia presenting with extramedullary leukemic tumors (EML)...
  37. ncbi request reprint Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemia
    Donna L Johnston
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Br J Haematol 123:431-5. 2003
    ..However, five of six evaluable patients with colonies negative for monosomy 7 entered remission. These data support the hypothesis that leukaemic involvement of early progenitor cells affects the response to induction chemotherapy...
  38. ncbi request reprint Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group
    William G Woods
    AFLAC Cancer Center, Emory University Children s Healthcare, Atlanta, GA, USA
    J Clin Oncol 20:434-40. 2002
    ..We report the first large prospective study of children with myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) treated in a uniform fashion on Children's Cancer Group protocol 2891...